Pharmacological Analysis of Xuanfei Huazhuo Prescription in Treatment of Coronavirus Disease-2019

LIU Dong-ling; WANG Hao-jia; REN Wei-yu; SU Jing; ZHENG Yi-jun; HOU Wen-qian; JIN Xiao-jie; NING Yan-mei; LI Jia-wei; ZHANG Zhi-ming; LIU Yong-qi

doi:10.13422/j.cnki.syfjx.20201703

您当前的位置：

首页 >

文章列表页 >

Pharmacological Analysis of Xuanfei Huazhuo Prescription in Treatment of Coronavirus Disease-2019

更新时间：2023-07-12

- Pharmacological Analysis of Xuanfei Huazhuo Prescription in Treatment of Coronavirus Disease-2019
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 16, Pages: 40-49(2020)
- 作者机构：
  
  1.甘肃中医药大学甘肃省高校重大疾病分子医学与中医药防治研究重点实验室，教育部敦煌医学与转化重点实验室，兰州 730000
  2.兰州大学第一临床医学院，兰州 730000
  3.甘肃中医药大学附属医院，兰州 730000
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201703
  CLC： R2-0;R22;R285.5;R289
- Published Online：10 June 2020，
  
  Published：20 August 2020
- 稿件说明：
移动端阅览
刘东玲,王浩嘉,任伟钰等.宣肺化浊方治疗新型冠状病毒感染肺炎的网络药理学分析[J].中国实验方剂学杂志,2020,26(16):40-49.

LIU Dong-ling,WANG Hao-jia,REN Wei-yu,et al.Pharmacological Analysis of Xuanfei Huazhuo Prescription in Treatment of Coronavirus Disease-2019[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(16):40-49.
刘东玲,王浩嘉,任伟钰等.宣肺化浊方治疗新型冠状病毒感染肺炎的网络药理学分析[J].中国实验方剂学杂志,2020,26(16):40-49. DOI： 10.13422/j.cnki.syfjx.20201703.

LIU Dong-ling,WANG Hao-jia,REN Wei-yu,et al.Pharmacological Analysis of Xuanfei Huazhuo Prescription in Treatment of Coronavirus Disease-2019[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(16):40-49. DOI： 10.13422/j.cnki.syfjx.20201703.

摘要

目的

通过网络药理学以及现代药理学基础分析探讨宣肺化浊方治疗新型冠状病毒肺炎（COVID-19）的作用靶点及信号通路，阐述其可能的作用机制。

方法

从TCMSP和BATMAN-TCM数据库搜索宣肺化浊方各中药的化合物及靶点，使用GeneCards，NCBI以及CTD数据库检索COVID-19靶点；通过STRING数据库构建蛋白质相互作用网络。采用Cytoscape 3.7.0软件构建中药-归经网络图以及中药-化合物-关键靶点-疾病网络，利用Omicshare平台对共有靶点进行京都基因与基因组百科全书（KEGG）分析及基因本体（GO）分析。除此之外，检索多脏器损伤、免疫损伤以及重症急性呼吸综合征（SARS）的疾病靶点，将宣肺化浊方与之做映射，计算交集靶点占宣肺化浊方靶点的比例。

结果

宣肺化浊方共10味中药，其中有6味归肺经，5味归脾经，5味归胃经。化合物共409个，相对应的靶标2 271个。宣肺化浊方的靶点与新冠肺炎有8个相同的炎症因子，每个炎症因子对应多个化合物。宣肺化浊方与COVID-19有135个交集靶点，筛选得到36个关键靶点。KEGG通信号通路富集筛选得到172条信号通路（

0.05），GO分析得到生物过程结果有4 000个，细胞组成有254个，分子功能有408个（

0.05））。宣肺化浊方与各脏器损伤靶点和免疫损伤靶点的共有靶点较多，且共有靶点/XFHZP靶点的比例在7.6%~97.8%，宣肺化浊方与SARS有173个交集靶点。

结论

宣肺化浊方可能通过发挥抗炎、保护脏器损伤、免疫等作用治疗新冠肺炎，这将为治疗新冠肺炎药物的开发提供一定的理论依据。

Abstract

Objective

The targets and signaling pathways of Xuanfei Huazhuo prescription (XFHZP) for the treatment of coronavirus disease-2019 (COVID-19) were explored

and its possible action mechanisms were described through network pharmacology and basic analysis of modern pharmacology.

Method

The compounds and targets in XFHZP were collected through TCMSP and BATMAN-TCM databases. The targets of COVID-19 were studied by GeneCards

NCBI and CTD databases. The PPI network was constructed through STRING database. The networks of "herb-meridian" and "traditional Chinese medicines-compounds-targets-disease" were generated by Cytoscape 3.7.0. Then

Kyoto Encyclopedia of Genes and Genomes（KEGG） analysis and Gene Ontology（GO） analysis were made for shared targets through the Omicshare platform. In addition

the disease targets of multiple organ injury

immune injury and severe acute respiratory syndrome (SARS) were retrieved and then mapped with XFHZP. The ratio of intersection targets to XFHZP's targets was calculated.

Result

XFHZP has 10 traditional Chinese medicines in total

including 6 medicines with the meridian tropism to lung

5 medicines with the meridian tropism to the spleen and 5 medicines with the meridian tropism to the stomach. There were 409 compounds and 2 271 targets. There were 8 same inflammatory factors in targets between XFHZP and COVID-19

and each inflammatory factor corresponded to multiple compounds. XFHZP and COVID-19 had 135 intersection targets

and 36 key targets were screened out. A total of 172 signaling pathways were screened out through KEGG signal pathway enrichment (

0.05). There were 4 000 biological processes

254 cell components

and 408 molecular functions (

0.05) according to GO analysis. XFHZP had many common targets with various organ damage targets and immune damage targets

with the ratio of about 7.6%-97.8%. XFHZP had 173 intersection targets with SARS.

Conclusion

XFHZP may treat COVID-19 through anti-inflammatory

organ protecting and immune effects. It will provide a certain theoretical basis for the development of drugs for COVID-19.

关键词

Keywords

references

ZHU N , ZHANG D . A novel coronavirus from Patients with pneumonia in China,2019 [J]. N Engl J Med , 2020 , 382 ( 8 ): 727 - 733 .

国家卫生健康委员会 . 关于印发新型冠状病毒肺炎诊疗方案（试行第七版）的通知 [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml , 2020-03-04 / 2020-03-11 .

王鑫 , 张志明 , 王功臣 , 等 . “甘肃方剂”在新型冠状病毒肺炎防治中的应用策略分析 [J]. 中国实验方剂学杂志， 2020 ， 26 （ 16 ）: 21 - 25 .

RU J L , LI P , WANG J N , et al . TCMSP:a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform , 2014 , 6 : 13 .

LIU Z , GUO F , WANG Y , et al . BATMAN-TCM: a bioinformatics analysis tool for molecular mechANism of traditional Chinese medicine [J]. Sci Rep , 2016 , 6 : 21146 .

The UniProt Consortium . UniProt:the universal protein knowledgebase .[J]. Nucleic Acids Res , 2017 , 45 : D158 - D169 .

WANG Y , LIU Z , LI C , et al . Drug target prediction based on the herbs components:the study on the multitargets pharmacological mechanism of Qishenkeli acting on the coronary heart disease [J]. Evid Based Complement Alternat Med , 2012 , doi: 10.1155/2012/698531 http://dx.doi.org/10.1155/2012/698531 ．

SHANNON P , MARKIEL A , OZIER O , et al . Cytoscape:a software environment for integrated models of biomolecular interaction networks [J]. Genome Res , 2003 , 13 : 2498 - 2504 .

HUANG D W , SHERMAN B T , LEMPICKI R A . Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources [J]. Nature Protoc , 2009 , 4 ( 1 ): 44 - 57 .

冯全生 , 张之文 . 传承瘟疫学理论,构建中医疫病防治新体系 [J]. 成都中医药大学学报 , 2009 , 32 ( 4 ): 11 - 13 .

HUANG C L , WANG Y M , LI X W . et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet , 2020 , 395 : 497 - 506 .

杨家耀 , 苏文 , 乔杰 , 等 . 90例普通型新型冠状病毒肺炎患者中医证候与体质分析 [J]. 中医杂志 , 2020 ， doi: 11.2166.R.20200221.1513.004 http://dx.doi.org/11.2166.R.20200221.1513.004 .

史桐凡 , 周谷城 , 张利英 , 等 . 宣肺化浊加减方治疗新型冠状病毒肺炎40例临床疗效观察 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 16 ): 26 - 31 .

冯彩琴 , 张志明 , 张月梅，等 . 基于多靶点分子对接初探宣肺化浊方治疗新型冠状病毒肺炎的物质基础 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 16 ): 32 - 39 .

姜雪 , 孙森凤 , 王悦 . 麻黄成分及其药理作用研究进展 [J]. 化工时刊 , 2017 , 31 ( 5 ): 28 - 31 .

张明发 , 沈雅琴 . 羌活药理学研究 [J]. 中国执业药师 , 2008 , 5 : 28 - 30 .

杨志军 , 王娟娜 , 王栋才 , 等 . 相恶药对黄芩生姜配伍前后对大鼠湿热模型的清热燥湿作用的比较 [J]. 中国临床药理学杂志 , 2019 , 35 ( 17 ): 1898 - 1901 .

孟祥乐 , 李红伟 , 韩永龙 , 等 . 栀子-连翘药对清热，利胆作用研究 [J]. 世界科学技术—中医药现代化 , 2015 , 17 ( 7 ): 1486 - 1491 .

曾颂 , 李书渊 , 吴志坚 , 等 . 半夏镇咳祛痰的成分-效应关系研究 [J]. 中国现代中药 , 2013 , 15 ( 6 ): 452 - 455 .

张明发 , 沈雅琴 . 半夏提取物对呼吸和消化系统药理作用的研究进展 [J]. 抗感染药学 , 2017 , 14 ( 8 ): 1457 - 1462 .

王娇 , 熊瑛 , 熊彬 , 等 . 麻黄水提物雾化吸入对哮喘小鼠气道炎症的影响 [J]. 重庆医学 , 2013 , 42 ( 3 ): 304 - 307 .

王国光 , 施萍萍 , 江颖 . 广藿香挥发油成分及其药理研究 [J]. 内蒙古中医药 , 2011 , 30 ( 4 ): 49 - 50 .

于艳 , 贾天柱 , 才谦 . 茅苍术及其麸炒品对胃溃疡大鼠抗炎作用的比较研究 [J]. 中国中药杂志 , 2016 , 41 ( 4 ): 705 - 710 .

张宁 . 连翘主要有效成分的提取与药理作用 [J]. 世界最新医学信息文摘 , 2019 , 19 ( 91 ): 180 , 189 .

严士海 , 朱萱萱 , 孟达理 , 等 . 麻黄多糖对EAT小鼠外周血淋巴细胞亚群的影响 [J]. 中华中医药学刊 , 2008 , 26 ( 5 ) : 1069 - 1071 .

曾光 , 梁清华 , 游万辉 , 等 . 黄芩苷对T淋巴细胞增殖与活化的影响 [J]. 中药药理与临床 , 2007 , 23 ( 6 ): 20 - 22 .

李启照 . 浅析苍术多糖药理作用及应用研究 [J]. 广东化工 , 2012 , 39 ( 6 ): 99 - 100 .

刘超 , 高慧婕 , 朱玉贞 , 等 . 大黄素对小鼠的免疫调节作用及对脾细胞TNF- α 和IL-10表达的影响 [J]. 基础医学与临床 , 2018 , 38 ( 9 ): 1298 - 1302 .

张伟 , 张娟娟 , 郭庆丰 , 等 . 广藿香醇药理作用研究进展 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 3 ): 213 - 221 .

曹景文 , 任玲 , 王秋红 , 等 . 广陈皮总多糖对小鼠迟发型超敏反应的影响 [J]. 广东药科大学学报 , 2019 , 35 ( 6 ): 779 - 782 .

CHAI X , HU L , ZHANG Y , et al . Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection [J]. bioRxiv , 2020 , doi: 10.1101/2020.02.03.931766 http://dx.doi.org/10.1101/2020.02.03.931766 .

刘晓君 , 杨洁芳 . 黄芩苷对急，慢性肝损伤模型鼠的保护作用 [J]. 中国药房 , 2014 , 25 ( 15 ): 1374 - 1376 .

沙多依 , 杭永付 , 宋菲 , 等 . 北苍术炮制前后挥发油部位保肝作用比较研究 [J]. 现代中药研究与实践 , 2010 , 24 ( 4 ): 41 - 43 .

崔庆新 , 廖承美 , 姜民 , 等 . 复方赶黄草方中保肝护肝成分的鉴定和定量分析 [J]. 中国科技论文 , 2016 , 11 ( 24 ): 2761 - 2764,2769 .

魏文婷 , 李冰 , 贾晔然 , 等 . 慢性阻塞性肺疾病患者肺组织中缺氧诱导因子1 α 的表达变化 [J]. 中国病理生理杂志 , 2013 , 29 ( 9 ): 1700 - 1703 .

黄浪浪 , 王建安 , 徐驲 , 等 . 基于网络药理学的黄连解毒汤治疗新型冠状病毒肺炎机制研究 [J]. 中药材 , 2020 ， doi: 44.1286.R.20200228.1830.008 http://dx.doi.org/44.1286.R.20200228.1830.008 .

NAKAE S , LUNDERIUS C , HO L H , et al . TNF can contribute to multiple features of ovalbumin-induced allergic inflammation of the airways in mice [J]. J Allergy Clin Immunol , 2007 , 119 ( 3 ): 680 - 686 .

WAN Y S , SHANG J , RACHEL G , et al . Receptor recognition by novel coronavirus from Wuhan [J]. J Virol , 2020 , doi: 10.1128/JVI.00127-20 http://dx.doi.org/10.1128/JVI.00127-20 .

HAMMING I , TIMENS W , BULTHUIS M L C , et al . Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus.A first step in understanding SARS pathogenesis [J]. J Pathol , 2004 , 203 : 631 - 637 .

贺勇 , 干伟 , 张玫 , 等 . 临床生化检验指标在COVID-19疾病进展及治疗中的应用评价 [J]. 国际检验医学杂志 , 2020 , doi: 50.1176.R.20200311.1013.002 http://dx.doi.org/50.1176.R.20200311.1013.002 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Bioinformatics Reveals Mechanism of Xiezhuo Jiedu Precription in Treatment of Ulcerative Colitis by Regulating Autophagy

Data Mining and Experimental Validation of Total Ginsenosides Ameliorating Alcoholic Hepatitis

Mechanism of Xiezhuo Jiedu Recipe in Preventing Colorectal Adenoma in Mice Through miRNA-34a-5p/PI3K/Akt Signalling Pathway

Mechanism of Xiezhuo Jiedu Recipe Regulating Ferroptosis in Treatment of Ulcerative Colitis Based on Bioinformatics and Animal Experiments

Improvement of Colonic Mucosa Inflammatory Response in Mice with Ulcerative Colitis by Xiezhuo Jiedu Recipe Through miRNA-155-5p/JAK2/STAT3 Pathway

Related Author

KANG Xin

SUN Chaodi

LIU Jianping

REN Jie

DU Mingmin

ZHAO Yuan

LANG Xiaomeng

CHEN Shuling

Related Institution

Handan Hospital of TCM

Hebei Key Laboratory of Turbidity Toxin Syndrome

Hebei Key Laboratory of Gastroenterology Research of Integrated Traditional Chinese and Western Medicine

Hebei Provincial Hospital of Traditional Chinese Medicine（TCM）

National Experimental Teaching Demonstration Center of Basic Medicine， Guizhou Medical University

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰